We’re preparing the next edition of One Nucleus Highlights—our A4 printed and digital publication launching 9 November 2026, at BIO-Europe.
To reach our life science ecosystem with your expertise, you can submit a thought-leadership piece on a key theme felt to be shaping our industry and wider trends in the sector. Alternatively, you could place an advert to be seen in such a context in the eyes of your key customers.
Why Contribute?
Prime visibility – distributed at our high-profile in-person events, showcased on our website, and amplified through a social media campaign to…
For years, the instinct in drug discovery was simple: when a decision is hard, get more data. But that instinct has stopped paying off. The binding constraint today isn't volume—it’s fragmentation. Our latest white paper explores why the most valuable signals are hiding in the space between datasets that were never built to speak to one another.
Stop collecting and start connecting. Read the full analysis here: https://www.digital-science.com/lp/data-integration-challenge/
#DrugDiscovery #DataStrategy #BioTech #DigitalScience
In life sciences, "feeling" ready for the future isn’t a strategy—it’s a risk. Are you actually leading the field? Most organizations are busy, but few know if they’re actually keeping pace with their peers.
We’re officially launching The Innovation Readiness Index: a diagnostic designed to stop the guesswork. We benchmark your capabilities across the 5 pillars that matter:
👉 Trust & Outcomes
👉 Governance & Flow
👉 AI Readiness
Participate in a brief diagnostic interview and receive a personalized gap analysis in a private 30-minute executive briefing.
🔗 See where you stand:…
As our sector continues to navigate change, we’re committed to creating accessible learning opportunities that support our community. Explore our latest courses and webinars, designed to help professionals at every career stage grow, connect, and thrive.________________________________________________
Spotlight: One Nucleus September TrainingLast Chance to Register!
8-9 September 2026 | IOSH Approved Biological Safety - Management and Practice (2-day course), Register Here...
This two-day, IOSH-approved course develops your biosafety expertise, particularly for Biological Safety…
Aware of just how busy diaries get for everyone and therefore every trip out of the office or lab must count, we have managed to coordinate with Marks & Clerk, Thermo Fisher Scientific and LBIC to deliver three informative events and peer-to-peer networking opportunities in one day. Three events, three topics, three locations - attend one, two or all three!
Start the Day: Choosing the Right Life Science Room to Be In - A London Seminar
The financial and people cost of attending events and conferences, when adding in travel, accommodation, preparation and the follow –up, can be one of the…
Partnership provides US-based sequencing and scalable consumer genomics infrastructure, including an at-home DNA collection, to deliver PrecisionLife’s personalized wellness reports to US consumers OXFORD, UK and NEW YORK, NY, August 26, 2026 - PrecisionLife, an AI-led health and life sciences company applying advanced analytics to complex chronic disease research, has selected Gencove as its consumer genetics platform partner to launch its DNA wellness reports in the United States. The milestone will enable US consumers to access personalized wellness information…
• Poster presentation at the ALS Association’s ALS Nexus conference, August 23-26
• Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action
• Data showed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in ALS mouse models
Stevenage, UK, 24 August 2026 - NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today presented a poster on preclinical and mechanistic data of its lead clinical asset…
Investment in new premises in London reflects significant milestone in Company’s growth, following $20 million Series B financing
Supports rapid scale-up and development of foundational AI imaging model, to improve clinical trial design across broader range of chest diseases
Cambridge, UK, 19 August 2026 – Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced the opening of its new office space in London, UK. The expansion into a second site will accommodate the…
Amsbio has launched a range of synthetic cell mimic products that eliminate the variability, fragility, and operational inefficiency inherent in traditional flow cytometry biological and polystyrene bead controls.
Researchers in pharmaceutical companies, biotechnology firms, CRO’s, clinical diagnostics and academic centres have long sought access to mass-produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies.
Benefitting from unmatched lot-to-lot consistency with coefficients of variation as low as 0.1%…
Cambridge UK: 18 August 2026
Penningtons Manches Cooper has renewed its partnership with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
Rachel Bradley, Partner at Penningtons Manches Cooper commented:
"Our long-standing relationship with One Nucleus reflects our shared commitment to supporting the success of innovative life sciences businesses. We are pleased to renew our partnership and continue engaging with a community that is driving…